We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

The Captureseq Technique Is More Accurate for Low Expressing Genes and Long Non-Coding RNAs

By LabMedica International staff writers
Posted on 24 Mar 2015
Print article
The powerful new CaptureSeq technique for gene analysis was shown to be superior for detecting and quantifying genes with low expression while showing little technical variation and accurately measured differential expression of long non-coding RNAs (lncRNAs).

Long non-coding RNAs (long ncRNAs, lncRNA) are non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

RNA sequencing (RNAseq) samples the majority of expressed genes infrequently, owing to the large size, complex splicing and wide dynamic range of eukaryotic transcriptomes. This results in sparse sequencing coverage that can hinder robust isoform assembly and quantification. RNA capture sequencing (CaptureSeq) addresses this challenge by using oligonucleotide probes to capture selected genes or regions of interest for targeted sequencing. The method involves enriching transcripts of interest by hybridizing them to magnetic bead-linked oligonucleotides that are tiled across the region of interest, allowing for targeted purification, multiplexed library preparation, and RNA sequencing at a high depth.

Investigators at the Garvan Institute of Medical Research (Sydney, Australia) recently compared quantitative real time-PCR (qRT-PCR), RNA-sequencing (RNAseq), and capture sequencing (CaptureSeq) in terms of their ability to assemble and quantify lncRNAs and novel coding exons across 20 human tissues.

They reported in the March 9, 2015, online edition of the journal Nature Methods that CaptureSeq achieved eightfold better sequence coverage for all standard concentrations tested, corresponding to the assembly of as few as 1,550 transcripts in the input RNA. In contrast, RNAseq could not reliably detect low standard concentrations, precluding the measurement of low-abundance standards. In the human leukemia cell line K562, an estimated 42.1% of RNA transcripts were better quantified using CaptureSeq. RNAseq and CaptureSeq performed similarly for 53.2% of transcripts.

While RNAseq performed better than CaptureSeq for the most highly expressed 4.6% of transcripts enriched for housekeeping, structural, and metabolic genes, genes with low expression in K562 cells for which CaptureSeq provided superior quantitative accuracy were enriched for transcription factors and genes associated with cancer or other human diseases.
Finally, the investigators identified 13,796 loci that generated 45,399 lncRNA isoforms, of which 27,596 were previously unknown, with 20.6% more exons and 13.5% more introns compared with previous annotations.

Related Links:
Garvan Institute of Medical Research


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more